Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Closes Sale of Discovery Research Business

NEW YORK (GenomeWeb News) — Tripos took a step closer to dissolution today after announcing it has closed the sale of its UK-based Discovery Research business to Commonwealth Biotechnologies.
The deal, which was penned in May, could be worth a total of $2.15 million depending on certain factors.
Tripos President and CEO John McAlister said the sale is “an important step in the completion of the dissolution and liquidation of Tripos and the distribution of the remaining proceeds to our stockholders later this year.”
The divestiture makes Tripos a shell company. It will ask the Nasdaq Global Market to delist its shares and will seek to be listed on the OTC Bulletin Board.
If the OTC BB is not available, Tripos said it plans to close trading in the company’s stock.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.